ArticleChemical biology & drug design2026
Discovery of Potent EGFR Inhibitors for Del19 and L858R/T790M Mutants Through Structure-Based Virtual Screening and Biological Evaluation.
Ting Xu, Yuchen Zhao, Mengfei Chen, Lijuan Zuo, Hanshuang Cai, Yuguo Liu, Chuanfeng Liu, Jing Shi
Abstract read
In one paragraphArticle in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Ting XuDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Yuchen ZhaoDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Mengfei ChenDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Lijuan ZuoTaian Central Hospital General ICU Zone 2, Taian, China.
Hanshuang CaiDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Yuguo LiuDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Chuanfeng LiuDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.ORCID https://orcid.org/0000-0003-4775-0143 Jing ShiDepartment of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Funding
National Natural Science Foundation of China 22507064Natural Science Foundation of Shandong Province ZR2022MH243Natural Science Foundation of Shandong Province ZR2023LZY008Natural Science Foundation of Shandong Province ZR2025LMB029Natural Science Foundation of Shandong Province ZR2025LSW009Shandong Province Traditional Chinese Medicine Science and Technology Project Z20243904
6 · The paper itselfAbstract
Epidermal growth factor receptor (EGFR) mutation-mediated drug resistance represents a major clinical challenge in the treatment of non-small cell lung cancer (NSCLC). In this study, the lead compound XJ2-2 was identified through structure-based virtual screening. It exhibited potent anti-proliferative activity against both EGFR
Indexed as
Antineoplastic AgentsErbB ReceptorsProtein Kinase InhibitorsAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationDrug Resistance, NeoplasmHumansLung NeoplasmsMiceMolecular Docking SimulationMutationStructure-Activity RelationshipAntineoplastic AgentsErbB ReceptorsProtein Kinase Inhibitorsdrug resistanceEGFRDel19EGFR inhibitorEGFRL858R/T790Mstructure‐based virtual screening
Identifiers
PMID42723470
PMCPMC13563102
What OpenQuestion holds
Textmetadata
Read underepoch 390